Northstar Investment Advisors LLC Sells 900 Shares of Bristol-Myers Squibb Co (BMY)
Northstar Investment Advisors LLC lessened its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,210 shares of the biopharmaceutical company’s stock after selling 900 shares during the quarter. Northstar Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $2,194,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of the business. Arlington Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 40.0% in the fourth quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 400 shares in the last quarter. Cypress Capital Management LLC WY lifted its stake in shares of Bristol-Myers Squibb by 154.7% in the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 1,160 shares in the last quarter. CLS Investments LLC lifted its stake in shares of Bristol-Myers Squibb by 194.3% in the third quarter. CLS Investments LLC now owns 2,575 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 1,700 shares in the last quarter. Highwater Wealth Management LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $170,000. Finally, Selective Wealth Management acquired a new stake in Bristol-Myers Squibb during the third quarter valued at approximately $184,000. Institutional investors own 72.68% of the company’s stock.
BMY has been the topic of several research reports. Citigroup cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $62.00 to $57.00 in a research note on Monday, October 22nd. JPMorgan Chase & Co. upped their price objective on Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, October 8th. Credit Suisse Group restated a “hold” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research note on Thursday, December 13th. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, October 22nd. Finally, Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, October 1st. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have assigned a buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.56.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.18. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. Equities analysts expect that Bristol-Myers Squibb Co will post 3.88 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 1st. Shareholders of record on Friday, January 4th will be given a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.46%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Thursday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is 54.49%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: What Are Treasury Bonds?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.